Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?
An erratum to this article was published (Pituitary, Dec 2023 ↗)
Authors' conclusion
Care trajectories were highly individualized based on patient and tumor characteristics, as well as the multidisciplinary team's assessment (need for alternative treatment, surgical chances and risks). Most patients were pretreated pharmacologically and had broad variation in timing of referral, undergoing surgery as last-resort treatment predominantly due to DA intolerance. High quality imaging and multidisciplinary consultations with experienced neurosurgeons and endocrinologists enabling treatment tailored to patients' needs were prerequisites for adequate counseling in treatment of patients with prolactinoma.
Study context
- Population
- Consecutive patients with prolactinoma undergoing surgery 2017–2019 at the referral center (PRolaCT study); 77.5% female, median age 26.5 (14–63) years
- Participants
- 40 patients
- Outcome
- Care trajectories and rationale for surgery (indications for surgery)
Methodological detailsobservational, consecutive patients, referral centre, Care trajectories divided into three phases: diagnosis and initial treatment, endocrine treatment at the referral center (RC), surgical treatment
- Observational
- Consecutive patients
- Referral centre
- Care trajectories divided into three phases: diagnosis and initial treatment, endocrine treatment at the RC, surgical treatment
Main finding
As reported in the abstract
Dopamine agonist (DA) intolerance
n = 31, 77.5%
DA resistance
n = 6, 15.0%
Patient/physician preference
n = 3, 7.5%
Observational data: associations, not effects.
Further findings
Pretreatment
- Pretreated with DA
- n = 39 (97.5%)
- Pretreated with surgery
- n = 3 (7.5%)
Disease duration at surgery
- Median disease duration at surgery (years)
- 4 (0-27)
Remission after surgery with total resection as primary goal · 6 months postoperatively
Patients
- Primary surgical goal total resection
- 38 (95.0%)
- Biochemical remission
- 23 (62.2%)
- Clinical remission
- 6 (16.2%)
- Missing data n = 1
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →